Ccj. Carpenter et al., ANTIRETROVIRAL THERAPY FOR HIV-INFECTION IN 1998 - UPDATED RECOMMENDATIONS OF THE INTERNATIONAL AIDS SOCIETY USA PANEL, JAMA, the journal of the American Medical Association, 280(1), 1998, pp. 78-86
Objective.-To provide recommendations for antiretroviral therapy based
on information available in mid-1998. Participants.-An international
panel of physicians with expertise in antiretroviral research and care
of patients with human immunodeficiency virus (HIV) infection, first
convened by the International AIDS Society-USA in December 1995. Evide
nce.-The panel reviewed available clinical and basic science study res
ults (including phase 3 controlled trials; clinical, virologic, and im
munologic end point data; data presented at research conferences; and
studies of HIV pathophysiology); opinions of panel members were also c
onsidered. Recommendations were limited to drugs available in mid-1998
. Consensus Process.-Panel members monitor new clinical research repor
ts and interim results. The full panel meets regularly to discuss how
the new information may change treatment recommendations. Updated reco
mmendations are developed through consensus of the entire panel at eac
h stage of development. Conclusions.-Accumulating data from clinical a
nd pathogenesis studies continue to support early institution of poten
t antiretroviral therapy in patients with HIV infection. A variety of
combination regimens show potency, expanding choices for initial regim
ens for individual patients. Plasma HIV RNA assays with increased sens
itivity are important in monitoring therapeutic response; however, mor
e data are needed to determine precisely the HIV RNA levels that defin
e treatment failure. Long-term adverse drug effects are beginning to e
merge, requiring ongoing attention. Some issues regarding optimal long
-term approaches to antiretroviral management are unresolved. The incr
eased complexity in HIV management requires ongoing monitoring of new
data for optimal treatment of HIV infection.